home / stock / kros / kros news


KROS News and Press, Keros Therapeutics Inc. From 11/06/23

Stock Information

Company Name: Keros Therapeutics Inc.
Stock Symbol: KROS
Market: NASDAQ
Website: kerostx.com

Menu

KROS KROS Quote KROS Short KROS News KROS Articles KROS Message Board
Get KROS Alerts

News, Short Squeeze, Breakout and More Instantly...

KROS - Keros Therapeutics GAAP EPS of -$1.33

2023-11-06 13:19:56 ET More on Keros Therapeutics Seeking Alpha’s Quant Rating on Keros Therapeutics Historical earnings data for Keros Therapeutics Financial information for Keros Therapeutics For further details see: Keros Therapeutics GAAP EPS o...

KROS - Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results

LEXINGTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disord...

KROS - Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition

LEXINGTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunct...

KROS - Expected US Company Earnings on Thursday, November 2nd, 2023

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

KROS - Expected earnings - Keros Therapeutics Inc.

Keros Therapeutics Inc. (KROS) is expected to report $-1.34 for Q3 2023

KROS - Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

LEXINGTON, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunct...

KROS - Keros Therapeutics GAAP EPS of -$1.27

2023-08-07 08:54:33 ET Keros Therapeutics press release ( NASDAQ: KROS ): Q2 GAAP EPS of -$1.27. Keros’ cash and cash equivalents as of June 30, 2023 was $322.0 million compared to $279.0 million as of December 31, 2022. For further details see: Keros...

KROS - Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

LEXINGTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disord...

KROS - Catalyst Watch: Wayfair and Kellogg events, Alibaba earnings and AI hacking test at Def Con

2023-08-04 15:00:42 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...

KROS - Keros Therapeutics: Hematological Therapies Continue To Advance

2023-08-02 13:19:28 ET Summary Keros Therapeutics is a biopharmaceutical company focused on developing treatments for hematological and musculoskeletal disorders. The company's financials show increased investment in R&D and organizational growth, with a net loss of $35.8 mill...

Previous 10 Next 10